PubMed Health⌕ Search

Biomedical subjects

V Adamo

Publications and source records attributed to V Adamo.

At least 37 records · Page 2Linked to original sources
PubMed1997

Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

The aim of this study was to evaluate three active agents, bleomycin (BLM), epirubicin and carboplatin in a new combination (BECA) in terms of feasibility, activity and toxicity in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. From April 1992 to February 1993 15 pts (12M/3F), median age 53 years, all pretreated (6 surgery + radiotherapy; 3 radiotherapy + chemotherapy; 6 radiotherapy), were treated with BLM 15 mg/m2 days 1-14; epirubicin 30 mg/m2 days 1-14 and carboplatin 300 mg/m2 day 1 every 28 days. In the 14 evaluable pts we observed 1 complete response, CR (7.1%), 4 partial responses, PR (28.6%), 5 stable disease, SD and 4 disease progression, PD with an overall response of 35.7%. The treatment was globally well tolerated, 1 pt with grade 3 leukopenia and 1 pt with grade 3 thrombocytopenia, 1 pt with grade 3 emesis and 1 pt with grade 3 mucositis. At the last follow-up the duration of CR was 34 months, the duration of PRs were respectively 22-10-10-7 months, but the SD ranged from 4 to 6 months. The overall median survival was 8 months (3-36), 14 for responders and 4 for non-responders. This final report seems to confirm the activity and efficacy of the BECA regimen, suitable for outpatient administration with an overall response equal to other more aggressive combinations.

Adult↗
PubMed1997

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

PURPOSE: The nucleoside analog, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small-cell lung cancer (NSCLC). Its combination with cisplatin in preclinical models suggested synergy between the two drugs. The aim of the study was to evaluate the clinical efficacy and toxicity of the cisplatin-gemcitabine combination in advanced NSCLC. PATIENTS AND METHODS: Forty-eight consecutive previously untreated NSCLC patients entered the trial from January to June 1994. The median age was 60 years (range, 37 to 70) and performance status (PS) was 0 or 1; 22 patients had unresectable stage III disease (21 stage IIIB and one stage IIIA) and 26 had stage IV disease. Gemcitabine 1 g/m2 was administered weekly (days 1, 8, and 15) followed by a 1-week rest and cisplatin 100 mg/m2 on day 2 of each 28-day cycle. Survival and response were determined in accordance with the intention-to-treat principle in all enrolled patients. RESULTS: Of 48 assessable patients, one (stage IV) had a complete response (CR) and 25 achieved a partial response (PR). The overall response rate was 54% (95% confidence interval [CI], 40% to 68%). Thrombocytopenia was the main side effect, with 52% of patients experiencing grade III to IV toxicity, which was usually short-lived and responsible for the omission of gemcitabine administration on day 15 in 50% of chemotherapy courses. The median survival time was 61.5 weeks (95% CI, 40 to 71). CONCLUSION: The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects. The regimen deserves further careful evaluation in a phase III prospective randomized trial.

Adult↗
PubMed1996

[Bacterial endocarditis in an infectious diseases department: our experience].

The infective endocarditis remains a serious disease. The microbiologic, immunologic and technologic researches have contributed to the diagnosis and cure of the disease. The Authors report the results on ten cases of infective endocarditis that came to their observation in the last five years. They emphasize the more important epidemiologic aspects, the role of the laboratory and instrumental results to define an early diagnosis and the best results about of the therapies used

English Abstract↗
PubMed1995

Concurrent carboplatin and radiotherapy in the treatment of squamous cell carcinoma of the head and neck, stage IV. Preliminary data of a phase II study.

About two-thirds of the patients with squamous cell carcinoma of the head and neck (SCCHN) are diagnosed when the disease is in a locoregionally advanced stage. If surgery is not advisable, radiotherapy is the only treatment presently available to obtain radicality. In order to improve the therapeutic efficacy of radiotherapy (RT), chemotherapy has been associated with it with the aim of eradicating possible micrometastatic foci outside the radiotherapic fields and to enhance the cytotoxic effects of radiation. Results with concomitant chemoradiotherapy have been encouraging. We carried out a phase II study with the combination of carboplatin 300 mg/m2 every 21 days and RT at conventional doses in SCCHN stage IV (non M1). We obtained an overall response of 85.7% with an 18-month survival of 70%. The toxicity was moderate. These results encourage us to continue the accural of patients.

Adult↗
PubMed1994

[Synchronous tumors of the colon].

Although rare, synchronous tumors of the colon represent an important clinical manifestation of cancer of the colon. The paper reports a study carried out in 437 patients with the aim of evaluating the incidence of synchronous tumours and identifying the most useful diagnostic tools for diagnosis. On the basis of the results obtained the authors conclude that the incidence of synchronous tumours of the colon ranges between 1-3% and that in comparison to other methods pancolonoscopy enables a complete diagnosis for a prophylactic approach to multiple tumours.

Adenocarcinoma↗
PubMed1994

[Chondrocalcinosis and diabetes mellitus. The clinico-statistical data].

Chondrocalcinosis is an important, common, age-related joint disease. Its characteristic is the deposit of calcium pyrophosphate dihydrate crystals in hyaline and fibrous cartilages. Occasionally, it is a familial disorder; more often, it is a sporadic disease of adults sometimes in association with hormonal and metabolic disorders. The relationship between CC and diabetes mellitus (DM) is disputed. In this study the prevalence of radiographic CC (knee and/or wrist) in 184 DM patients was evaluated. For comparison two matched groups without DM were studied: i) 184 consecutive unselected out-patients seem in Rheumatology Department of Ancona University with X-rays of knee and/or wrist; ii) 184 consecutive unselected outpatients observed in a Radiology Department with X-rays of knee and/or wrist. No statistical difference was found between the prevalence of CC in DM patients vs controls. Moreover 113 CC patients were studied. No statistical difference was observed between the prevalence of DM and impaired glucose tolerance in CC patients vs controls. These results may suggest that there is no relationship between CC and diabetes mellitus, as other studies have recently shown.

Adult↗
PubMed1993

Ondansetron plus dexamethasone in the control of high dose cisplatin-induced emesis.

Twenty-two patients who underwent chemotherapy with cisplatin (CDDP) at doses > 100 mg/m2 also received antiemetic treatment comprised of the combination of ondansetron plus dexamethasone. The results obtained have shown a good activity from this combination with these high doses of CDDP, with a response of 81.8% (complete+major protection). There were also three therapeutic failures in patients with a few negative prognostic characteristics. It is our intention to use a benzodiazepine and adequate psychological support in an attempt to increase the response percentages in these kinds of patients.

Adult↗
PubMed1992

Unusual relapse of hepatocellular carcinoma.

The authors report a patient with iatrogenic dissemination of hepatocellular carcinoma (HCC). A 65-year-old Caucasian man was found to have a moderately well-differentiated HCC diagnosed by laparoscopy and biopsy; the patient had atypical left liver lobe resection. Thirty-three months after definitive surgery a double relapse was found at the site of the previous laparoscopy and at the surgical scar; no other metastases were found. Surgical procedure for removal of these lesions was performed, and the patient received complementary radiation therapy. At 30 months of follow-up, the patient is alive and disease free. The risk of neoplastic seeding through biopsy and improved safety in surgical techniques justify the omission of diagnostic biopsy in patients who have surgical procedures.

Aged↗
PubMed1989

VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer.

We report the results obtained in the treatment of 52 advanced non-small-cell lung cancer patients with the combination chemotherapy VP16 (120 mg/m2 i.v., days 1-2-3), epirubicin (50 mg/m2 i.v., day 1) and procarbazine (100 mg/m2 p.o., days 1 through 8). The courses were repeated every 21 days. No patient had been pretreated. A median of 5 courses was administered. Partial response was obtained in 33% and no change in 21% of patients. Median remission time was 6.5 months, and median survival of responders was 10 months. The best response rate and median survival were obtained in the lowest grade performance status patients and in locally advanced disease patients. Major chemotherapy related toxicities were grade 1-2 leukopenia and grade 2-3 alopecia.

Adult↗
PubMed1989

Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur.

29 evaluable patients with advanced and/or metastatic epidermoid carcinomas of the head and neck were treated with a combination of bleomycin, methotrexate and ftorafur. 3 complete remission, 12 partial remission (objective response 51.7%), 10 stable disease and 4 progressed disease were obtained, with the best responses in the oral cavity and skin carcinomas. The grade of performance status and the pretreatments affected the response, with a very high response rate in nonpretreated patients, where objective results were obtained in all cases. The toxicity was very mild. We believe that this combination can be recommended for epidermoid carcinomas of the skin and oral cavity, considering its high response rate, feasibility and low toxicity.

Adult↗
PubMed1989

Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade.

Eighty-seven women with advanced cervical carcinoma were treated, in 10 years, with systemic antiblastic chemotherapy using 4 different regimens in 4 successive periods: first VBM, then MAB, CDDP and finally BMFt. Selection of a regimen different than the initial one aimed to obtain a better response and less toxicity. As a whole, 25% positive responses (CR and PR) and an SD which varied from 31.4% to 58.3% were obtained. Among the regimens used, the one with bleomycin, methotrexate and ftorafur had a response rate (OR + SD) of 75% which is higher than what was obtained with regimens VBM and MAB and is similar to CDDP. Less toxicity with greater compliance were shown.

Adult↗
PubMed1988

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.

From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days 1 and 8; epirubicin or doxorubicin 50 mg/m2 IV on day 1; cyclophosphamide 500 mg/m2 IV on day 1 (FEC or FAC). Cycles were repeated every 21 days until progression or to cumulative doses of 700 mg/m2 for epirubicin and 550 mg/m2 for doxorubicin. Dose reductions were applied according to the standard criteria. Activity was evaluated in 443 patients (222 in the FEC arm and 221 in the FAC arm). The two experimental groups were comparable in age, performance status, menopausal status, histology, previous treatments, and site of the disease. The overall response rate (complete response and partial response [CR + PR]) was not significantly different: 53.6% for FEC and 56.5% for FAC. The median time to progression was 273 days for FEC and 314 days for FAC; the median survival time was 591 and 613 days, respectively. Leukopenia, anemia, nausea, and vomiting were significantly lower in patients treated with FEC. As for cardiotoxicity, four cases of congestive heart failure (CHF) were recorded among patients treated with FAC while only one was observed in the FEC group. These results indicate that epirubicin in a combination chemotherapy regimen is as active as doxorubicin and is significantly less toxic.

Adult↗
PubMed1988

Urticarial vasculitis progressing to systemic lupus erythematosus.

We encountered a patient with urticarial vasculitis. The lesions were urticarial target-shaped, lasting approximately 48 to 72 hours, accompanied by burning, photophobia, fever, and arthralgia. Initially, all studies for thyroid disease and lupus erythematosus were negative. However, after 20 months of follow-up, the patient developed autoimmune thyroidosis and systemic lupus erythematosus. We describe an unusual progression of this disease.

Adult↗